Literature DB >> 10932964

Insulin analogues and management of diabetes mellitus.

B Vaidyanathan1, P S Menon.   

Abstract

The introduction of insulin analogues, of which insulin lispro is the prototype, marks a very important milestone in the management of patients with diabetes mellitus. It differs from regular human insulin in its quicker onset and shorter duration of action. In various clinical trials, insulin lispro was found to be superior to regular human insulin in controlling postprandial hyperglycemia without increasing the risk of hypoglycemia. It improved the quality of life of diabetic patients by providing more flexibility to meal plans. Recently, another short acting insulin analogue called insulin aspart has been tried in clinical studies with benefits similar to insulin lispro. The turn of the millennium is now witnessing the development of long acting insulin analogues like insulin glargine, which can provide continuous low-level basal insulin concentrations similar to natural settings. In this review, we discuss the potential of insulin analogues in the modern management of diabetes with emphasis on insulin lispro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10932964     DOI: 10.1007/bf02859462

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  42 in total

1.  Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.

Authors:  N Attia; T W Jones; J Holcombe; W V Tamborlane
Journal:  Diabetes Care       Date:  1998-05       Impact factor: 19.112

2.  Effects of a short-acting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus.

Authors:  A Caixàs; A Pérez; A Payés; C Otal; G Carreras; J Ordóñez-Llanos; J Reviriego; J H Anderson; A de Leiva
Journal:  Metabolism       Date:  1998-04       Impact factor: 8.694

3.  Insulin lispro in CSII: results of a double-blind crossover study.

Authors:  B Zinman; H Tildesley; J L Chiasson; E Tsui; T Strack
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

4.  Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes.

Authors:  B Rami; E Schober
Journal:  Eur J Pediatr       Date:  1997-11       Impact factor: 3.183

Review 5.  Hypoglycemia and insulin analogues: is there a reduction in the incidence?

Authors:  L Heinemann
Journal:  J Diabetes Complications       Date:  1999 Mar-Apr       Impact factor: 2.852

6.  Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group.

Authors:  F Holleman; H Schmitt; R Rottiers; A Rees; S Symanowski; J H Anderson
Journal:  Diabetes Care       Date:  1997-12       Impact factor: 19.112

7.  [Lispro analog and quality of life].

Authors:  N Tubiana-Rufi; G Munz-Licha
Journal:  Diabetes Metab       Date:  1997-09       Impact factor: 6.041

Review 8.  Are presently available insulin analogues clinically beneficial?

Authors:  M Berger; L Heinemann
Journal:  Diabetologia       Date:  1997-07       Impact factor: 10.122

9.  Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.

Authors:  S R Mudaliar; F A Lindberg; M Joyce; P Beerdsen; P Strange; A Lin; R R Henry
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

Review 10.  Insulin lispro: its role in the treatment of diabetes mellitus.

Authors:  R K Campbell; L K Campbell; J R White
Journal:  Ann Pharmacother       Date:  1996-11       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.